{"classes":[{"categories":[{"measurements":[{"comment":"95% Confidence Interval was incalculable due to an insufficient number of events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"2"},{"groupId":"OG001","lowerLimit":".8","upperLimit":"2.5","value":"1.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Graphically summarized using the methods of Kaplan and Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive alisertib PO BID on days 1-7. Patients unable to achieve CR after course 4 also receive rituximab IV on day 1 of courses 5-12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nalisertib: Given PO\n\nrituximab: Given IV\n\nlaboratory biomarker analysis: Laboratory correlative studies will be performed","id":"OG000","title":"Cohort A (Alisertib, Rituximab)"},{"description":"Patients receive alisertib as in Cohort A. Patients achieving SD or asymptomatic progressive disease after 2 courses also receive rituximab IV on day 1 of courses 3-10. Patients unable to achieve CR by course 4, receive rituximab as in Cohort A. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nalisertib: Given PO\n\nrituximab: Given IV\n\nlaboratory biomarker analysis: Laboratory correlative studies will be performed","id":"OG001","title":"Cohort B (Alisertib, Rituximab)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from study entry to the time of progression and/or death, assessed up to 1 year","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}